ArticleHeliyon2024
Prospects of
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phytomedical Properties ofViruses · 2025Review
- In Vitro Determination of Antimicrobial, Antioxidant and Antiviral Properties of Greek Plant Extracts.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viruses cause various human diseases, some of which become pandemic outbreaks lack effective treatments and vaccines. This study gathered data on Carica papaya's antiviral effects against various human viruses, highlighting its potential as a natural treatment. Through Method: ology: Research papers on antiviral activity of Carica papaya were identified by using specific keywords in PUBMED, Google Scholar, and ScienceDirect databases. Articles published between January 2015 and March 2024 were screened for inclusion. Eligible studies utilized Carica papaya leaves (powder or juice) or fruits to investigate their effects against human viral infections. Each selected study applied either qualitative or quantitative antiviral assays to assess the efficacy of Carica papaya in combating human viruses. Results: Fifteen studies went through assessment for antiviral properties of Carica papaya, 7 (46.67 %) of them displayed significant activity against the dengue virus, while 1 study (6.67 %) demonstrated moderate/less effectiveness against dengue serotype-2. Two studies (13.33 %) found no anti-dengue effects. Additionally, Carica papaya exhibited strong antiviral activity against SARS-CoV-2 in 2 studies (13.33 %). One study (6.67 %) showed inhibition of both dengue serotype-2 and chikungunya, and 1 study (6.67 %) each demonstrated inhibitory effects against human immunodeficiency virus and Zika virus infections. Conclusion: The present study listed human diseases for which Carica papaya revealed significant antiviral effects against Dengue virus, Severe acute respiratory syndrome, Human immunodeficiency virus-I, Chikungunya virus and Zika virus suggesting its potential as a treatment candidate for all these viruses. However, the majority of the research involved
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.